A full list of inclusion and exclusion criteria is available in the protocol paper 31
A 2025 randomized pragmatic trial found that semaglutide resulted in a 15% greater reduction in HbA1c levels than common hormone treatments, suggesting a clinically meaningful advantage in glycemic lowering versus hormone-based comparators in that study population
The American Diabetes Association and American Association of Clinical Endocrinologists have not issued specific guidance endorsing compounded GLP-1 receptor agonists as equivalent alternatives to FDA-approved products
Similarly, whole foods digest more slowly, which stacks with semaglutide's gastric-emptying effects to extend fullness between meals
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
In animal data, retatrutide produced body-weight reductions closer to 30% or even 40% in some conditions